K43TW011987
Project Grant
Overview
Grant Description
Quantifying, explaining, and predicting survival after diagnosis of HIV-related Kaposi sarcoma in East Africa - project summary.
Among malignant complications of HIV infection in sub-Saharan Africa, one of the most common cancers in the pre-antiretroviral therapy (ART) era — Kaposi's sarcoma (KS) — continues to be amongst the most common in the ART era.
Despite a decline in mortality in the ART era, KS survival is still unacceptably poor, and many questions remain regarding mortality after KS diagnosis in the ART era. These questions span epidemiology and clinical management.
With much yet to be learned, and as a direct response to the urgent need for effective strategies to improve survival of patients with HIV-related KS, the overall goal of this mentored career development proposal is to support Dr. Helen Byakwaga in acquiring the knowledge and skills to become an independent investigator in clinical and translational HIV-associated cancer research, with a focus on efforts to reduce KS mortality among HIV-infected individuals in sub-Saharan Africa.
Dr. Byakwaga has developed a research proposal linked to a career development plan, both of which are supported by a multi-faceted mentoring team that will guide her in completing the research and transitioning to an internationally competitive independent scientist.
The specific aims are:
AIM 1: Determine excess risk of mortality associated with KS among HIV-infected adults in East Africa.
AIM 2: Identify potential biologic determinants of mortality among HIV-infected adults with a new diagnosis of KS.
AIM 3: Develop and validate a prediction model for mortality among individuals with HIV-related KS.
This project will determine the true magnitude of the impact of KS on mortality among HIV-infected individuals in the ART era, identify potential pathways that can be targeted to attenuate KS progression, and develop an algorithm to predict those at highest risk for death after KS diagnosis and for whom rapid interventions are most warranted.
Overall, this proposal describes a comprehensive menu of research and career development activities consisting of mentoring and coursework that will help Dr. Byakwaga to achieve her research objectives and become an independent researcher.
Among malignant complications of HIV infection in sub-Saharan Africa, one of the most common cancers in the pre-antiretroviral therapy (ART) era — Kaposi's sarcoma (KS) — continues to be amongst the most common in the ART era.
Despite a decline in mortality in the ART era, KS survival is still unacceptably poor, and many questions remain regarding mortality after KS diagnosis in the ART era. These questions span epidemiology and clinical management.
With much yet to be learned, and as a direct response to the urgent need for effective strategies to improve survival of patients with HIV-related KS, the overall goal of this mentored career development proposal is to support Dr. Helen Byakwaga in acquiring the knowledge and skills to become an independent investigator in clinical and translational HIV-associated cancer research, with a focus on efforts to reduce KS mortality among HIV-infected individuals in sub-Saharan Africa.
Dr. Byakwaga has developed a research proposal linked to a career development plan, both of which are supported by a multi-faceted mentoring team that will guide her in completing the research and transitioning to an internationally competitive independent scientist.
The specific aims are:
AIM 1: Determine excess risk of mortality associated with KS among HIV-infected adults in East Africa.
AIM 2: Identify potential biologic determinants of mortality among HIV-infected adults with a new diagnosis of KS.
AIM 3: Develop and validate a prediction model for mortality among individuals with HIV-related KS.
This project will determine the true magnitude of the impact of KS on mortality among HIV-infected individuals in the ART era, identify potential pathways that can be targeted to attenuate KS progression, and develop an algorithm to predict those at highest risk for death after KS diagnosis and for whom rapid interventions are most warranted.
Overall, this proposal describes a comprehensive menu of research and career development activities consisting of mentoring and coursework that will help Dr. Byakwaga to achieve her research objectives and become an independent researcher.
Funding Goals
THE JOHN E. FOGARTY INTERNATIONAL CENTER (FIC) SUPPORTS RESEARCH AND RESEARCH TRAINING TO REDUCE DISPARITIES IN GLOBAL HEALTH AND TO FOSTER PARTNERSHIPS BETWEEN U.S. SCIENTISTS AND THEIR COUNTERPARTS ABROAD. FIC SUPPORTS BASIC BIOLOGICAL, BEHAVIORAL, AND SOCIAL SCIENCE RESEARCH, AS WELL AS RELATED RESEARCH TRAINING AND CAREER DEVELOPMENT. THE RESEARCH PORTFOLIO IS DIVIDED INTO SEVERAL PROGRAMS THAT SUPPORT A WIDE VARIETY OF FUNDING MECHANISMS TO MEET PROGRAMMATIC OBJECTIVES.
Grant Program (CFDA)
Awarding Agency
Funding Agency
Place of Performance
Uganda
Geographic Scope
Foreign
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 9913% from $4,880 to $488,657.
The Infectious Diseases Institute was awarded
Predicting Survival of HIV-Related Kaposi Sarcoma in East Africa
Project Grant K43TW011987
worth $488,657
from National Cancer Institute in August 2021 with work to be completed primarily in Uganda.
The grant
has a duration of 4 years 9 months and
was awarded through assistance program 93.398 Cancer Research Manpower.
The Project Grant was awarded through grant opportunity Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 7/3/25
Period of Performance
8/25/21
Start Date
5/31/26
End Date
Funding Split
$488.7K
Federal Obligation
$0.0
Non-Federal Obligation
$488.7K
Total Obligated
Activity Timeline
Transaction History
Modifications to K43TW011987
Additional Detail
Award ID FAIN
K43TW011987
SAI Number
K43TW011987-4044400925
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Non-Domestic (Non-U.S.) Entity
Awarding Office
75NF00 NIH Fogarty International Center
Funding Office
75NC00 NIH National Cancer Institute
Awardee UEI
THLMFMXSXTC4
Awardee CAGE
SCX13
Performance District
Not Applicable
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Cancer Institute, National Institutes of Health, Health and Human Services (075-0849) | Health research and training | Grants, subsidies, and contributions (41.0) | $196,068 | 97% |
| John E. Fogarty International Center, National Institutes of Health, Health and Human Services (075-0819) | Health research and training | Grants, subsidies, and contributions (41.0) | $6,937 | 3% |
Modified: 7/3/25